scispace - formally typeset
C

Charles D. Papageorgiou

Researcher at Takeda Pharmaceutical Company

Publications -  18
Citations -  415

Charles D. Papageorgiou is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Crystallization & Heat transfer. The author has an hindex of 8, co-authored 18 publications receiving 288 citations. Previous affiliations of Charles D. Papageorgiou include Millennium Pharmaceuticals.

Papers
More filters
Journal ArticleDOI

Continuous-Flow Tubular Crystallization in Slugs Spontaneously Induced by Hydrodynamics

TL;DR: The slug-flow crystallizer as mentioned in this paper is a continuous crystallizer with the potential to provide improved control of crystal properties, improved process reproducibility, and reduced scale-up risk.
Journal ArticleDOI

Indirect Ultrasonication in Continuous Slug-Flow Crystallization

TL;DR: In this article, an indirect ultrasonication-assisted nucleation process is designed to vary the seed generation rate during operation independent of mass flow rate, by varying the ultrasonization power.
Journal ArticleDOI

The Pharmaceutical Drying Unit Operation: An Industry Perspective on Advancing the Science and Development Approach for Scale-Up and Technology Transfer

TL;DR: In this paper, the authors survey current practices within the industry for drying development related to chemical and physical stability, drying kinetics, and powder properties and highlight common development gaps for improving drying development workflows within the pharmaceutical industry.
Journal ArticleDOI

Development and Scale-up of a Flow Chemistry Lithiation–Borylation Route to a Key Boronic Acid Starting Material

TL;DR: A flow chemistry process for the synthesis of a key boronic acid starting material was developed utilizing flow flash chemistry that allowed formation and subsequent productive reaction of an unstable organolithium intermediate.
Journal ArticleDOI

Application of model-free and model-based Quality-by-Control (QbC) for the efficient design of pharmaceutical crystallization processes

TL;DR: The design of pharmaceutical crystallization processes is a challenging engineering problem because of the specific and versatile quality requirements of the end-product, amplified by the tight regulatory requirements.